Business, energy, technology, markets and global industry news from Business News Today

Seagen

PharmaDeviceNews Seagen
Representative image: An oncology specialist reviews lung scans and clinical trial data as Pfizer’s sigvotatug vedotin Phase 3 survival miss shifts attention to second-line patients, biomarker strategy and first-line combinations.
Pharma & Biotech

Sigvotatug vedotin Phase 3 miss tests Pfizer’s case for integrin beta-6 targeted ADCs

Discover why Pfizer’s sigvotatug vedotin Phase 3 miss shifts attention to second-line patients, biomarkers and first-line combinations.

Read More
Representative image of oncology researchers reviewing molecular therapy data, reflecting Pfizer and Innovent Biologics’ global collaboration to advance antibody-drug conjugates, multispecific antibodies, and next-generation cancer medicines.
Pharma & Biotech

Why Pfizer’s $10.5bn Innovent Biologics deal matters for the next wave of cancer medicines

Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?

Read More